Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Please Tell Me It Is Only a Nightmare-The Proposed Dismantling of the United States Federal Research Infrastructure.

Diabetes care·2026
Same author

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design.

Diabetes, obesity & metabolism·2026
Same author

Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).

Diabetes care·2026
Same author

Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes.

Diabetes technology & therapeutics·2026
Same author

Everyone or Just Some? Cost-Effectiveness of General Population Versus Targeted Screening Strategies for Type 1 Diabetes in Canada.

Diabetes care·2026
Same author

Trial Interviews to Explore Glycogen Storage Disease Type Ia Patient Experiences Following Gene Therapy.

Journal of health economics and outcomes research·2026

Related Experiment Video

Updated: Jun 26, 2026

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination
04:50

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination

Published on: February 8, 2022

Vascular dysfunction in glycogen storage disease type I.

Angelina V Bernier1, Catherine E Correia, Michael J Haller

  • 1Division of Pediatric Endocrinology and Glycogen Storage Disease Program, Department of Pediatrics, University of Florida, Gainesville, FL 32610-0296, USA.

The Journal of Pediatrics
|December 23, 2008
PubMed
Summary
This summary is machine-generated.

Patients with Glycogen Storage Disease (GSD) I show arterial dysfunction, indicated by increased carotid intima media thickness and augmentation index, suggesting a higher risk for cardiovascular disease.

More Related Videos

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining
09:42

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining

Published on: December 23, 2014

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue
02:30

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue

Published on: October 24, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination
04:50

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination

Published on: February 8, 2022

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining
09:42

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining

Published on: December 23, 2014

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue
02:30

Radiochemical Assessment of Glycogen Synthase Enzyme Activity in Animal Tissue

Published on: October 24, 2025

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Vascular Biology

Background:

  • Glycogen Storage Disease (GSD) I is a rare inherited metabolic disorder.
  • Cardiovascular complications are a concern in patients with GSD I.
  • Noninvasive assessment of arterial health is crucial for risk stratification.

Purpose of the Study:

  • To evaluate cardiovascular disease risk in GSD I patients.
  • To assess arterial function and anatomy using noninvasive methods.
  • To compare arterial parameters between GSD I patients and healthy controls.

Main Methods:

  • Carotid intima media thickness (IMT), radial artery tonometry, and brachial artery reactivity were measured.
  • The study included 28 patients with GSD I and 23 control subjects.
  • Data were analyzed adjusting for age, sex, and body mass index.

Main Results:

  • GSD I patients exhibited significantly greater mean left distal IMT compared to controls (P = .002).
  • Radial artery tonometry revealed a higher augmentation index in the GSD I cohort (P < .001).
  • No significant difference in brachial artery reactivity was found between groups (P = .46).

Conclusions:

  • GSD I is associated with arterial dysfunction, evidenced by increased IMT and augmentation index.
  • These findings suggest an elevated risk of cardiovascular disease in patients with GSD I.
  • Noninvasive vascular assessments are valuable for monitoring GSD I patients.